Guizhou Yibai Pharmaceutical Co., Ltd. (SHA:600594)
China · Delayed Price · Currency is CNY 3.130
-0.080 (-2.49%)
Nov 13, 2026, 3:00 PM CST
SHA:600594 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 1,390 | 1,847 | 2,150 | 2,808 | 2,729 | 3,343 |
Other Revenue | 15.92 | 15.92 | 23.87 | 12.45 | 5.98 | 3.87 |
| 1,406 | 1,863 | 2,174 | 2,821 | 2,735 | 3,347 | |
Revenue Growth | -26.26% | -14.31% | -22.92% | 3.12% | -18.27% | -1.95% |
Cost of Revenue | 658.78 | 779.62 | 852.07 | 935.74 | 814.48 | 747.9 |
Gross Profit | 747.41 | 1,083 | 1,322 | 1,885 | 1,921 | 2,599 |
Selling, General & Admin | 864.07 | 1,113 | 1,453 | 1,590 | 1,533 | 1,979 |
Research & Development | 62.07 | 84.27 | 100.5 | 112.15 | 126.93 | 136.07 |
Other Operating Expenses | 47.19 | 31.46 | 31.96 | 42.66 | 11.62 | 43.16 |
Operating Expenses | 973.33 | 1,232 | 1,581 | 1,741 | 1,671 | 2,166 |
Operating Income | -225.92 | -148.68 | -258.95 | 143.79 | 249.46 | 433.12 |
Interest Expense | -5.96 | -23.37 | -26.39 | -21.64 | -37.48 | -35.13 |
Interest & Investment Income | 1.03 | 3.77 | 7.37 | 7.1 | 7.32 | 42.1 |
Other Non Operating Income (Expenses) | -12.24 | -1.46 | -18.93 | -5.55 | -14.82 | -10.58 |
EBT Excluding Unusual Items | -243.09 | -169.75 | -296.9 | 123.7 | 204.48 | 429.5 |
Impairment of Goodwill | -131.26 | -131.26 | -32.78 | - | -613.62 | -138.4 |
Gain (Loss) on Sale of Investments | 0.15 | -0.21 | - | - | -0.17 | - |
Gain (Loss) on Sale of Assets | -9.65 | -31.17 | -0.96 | -0.51 | 27.21 | -2.93 |
Asset Writedown | -11 | -0.06 | -23.5 | -19.4 | -9.97 | -2.24 |
Other Unusual Items | 34.69 | 20.71 | 21.62 | 28.53 | - | 24.42 |
Pretax Income | -360.17 | -311.75 | -332.52 | 132.32 | -392.07 | 310.37 |
Income Tax Expense | 32.78 | 23.59 | 2.15 | 40.96 | 46.19 | 79.57 |
Earnings From Continuing Operations | -392.95 | -335.34 | -334.67 | 91.36 | -438.26 | 230.79 |
Minority Interest in Earnings | -1.3 | 5.78 | 17.46 | 12.04 | 11.87 | 12.98 |
Net Income | -394.25 | -329.56 | -317.22 | 103.4 | -426.39 | 243.77 |
Net Income to Common | -394.25 | -329.56 | -317.22 | 103.4 | -426.39 | 243.77 |
Net Income Growth | - | - | - | - | - | 6.56% |
Shares Outstanding (Basic) | 782 | 785 | 789 | 789 | 793 | 791 |
Shares Outstanding (Diluted) | 782 | 785 | 789 | 789 | 793 | 791 |
Shares Change | -0.54% | -0.56% | -0.03% | -0.41% | 0.14% | -0.01% |
EPS (Basic) | -0.50 | -0.42 | -0.40 | 0.13 | -0.54 | 0.31 |
EPS (Diluted) | -0.50 | -0.42 | -0.40 | 0.13 | -0.54 | 0.31 |
EPS Growth | - | - | - | - | - | 6.57% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 100.57 | 221.71 | -9.45 | 247.23 | 22.38 | 486.43 |
Free Cash Flow Per Share | 0.13 | 0.28 | -0.01 | 0.31 | 0.03 | 0.61 |
Dividend Per Share | - | - | - | 0.066 | - | - |
Dividend Growth | - | - | - | -84.65% | - | - |
Gross Margin | 53.15% | 58.15% | 60.81% | 66.82% | 70.22% | 77.65% |
Operating Margin | -16.07% | -7.98% | -11.91% | 5.10% | 9.12% | 12.94% |
Profit Margin | -28.04% | -17.69% | -14.59% | 3.67% | -15.59% | 7.28% |
Free Cash Flow Margin | 7.15% | 11.90% | -0.43% | 8.77% | 0.82% | 14.54% |
EBITDA | -76.97 | 15.24 | -75.06 | 335.4 | 421.45 | 580.68 |
EBITDA Margin | -5.47% | 0.82% | -3.45% | 11.89% | 15.41% | 17.35% |
D&A For EBITDA | 148.95 | 163.93 | 183.9 | 191.61 | 171.99 | 147.56 |
EBIT | -225.92 | -148.68 | -258.95 | 143.79 | 249.46 | 433.12 |
EBIT Margin | -16.07% | -7.98% | -11.91% | 5.10% | 9.12% | 12.94% |
Effective Tax Rate | - | - | - | 30.96% | - | 25.64% |
Revenue as Reported | 416.22 | 1,863 | 2,174 | 2,821 | 2,735 | 3,347 |